Ten stocks fell sharply on Tuesday, bucking a mostly optimistic market sentiment, as investors took path from a flurry of profit-taking, industry developments, and weak outlook, among others.
Meanwhile, Wall Street’s major indices finished mixed, with the Dow Jones the only loser by 0.83 percent. The S&P 500 and the Nasdaq both jumped by 0.41 percent and 0.91 percent, respectively.
In this article, we spotlight the 10 big names with the largest losses during the session and break down the reasons behind their drop.
To come up with the list, we focused exclusively on stocks with a $2 billion market capitalization and 5 million shares in trading volume.
Photo by Anna Nekrashevich on Pexels
10. ImmunityBio Inc. (NASDAQ:IBRX)
ImmunityBio extended losses for a third day on Tuesday, shedding 4.19 percent to close at $5.95 apiece as investors continued to take profits after recording 14 straight days of gains last week.
For the entire month of January until Thursday, January 22, ImmunityBio Inc. (NASDAQ:IBRX) has already soared by 271 percent following a flurry of positive developments, including strong clinical trial results, a 700 percent sales jump from its therapy Anktiva, and expansion into international markets.
In other news, ImmunityBio Inc. (NASDAQ:IBRX) is set to announce detailed results of its QUILT-3.078 Phase 2 study evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progressive glioblastoma (GBM), as well as patients treated under single-patient INDs (spINDs) across first- to third-line disease.
As of last Thursday, the study has enrolled 23 patients with recurrent or progressive GBM who progressed following standard-of-care therapy, including surgery, radiation, and temozolomide-based chemotherapy.
The treatment has also demonstrated a manageable safety profile
Of the total number of enrollees, 19 remain alive, with four deaths reported to date.
9. Hecla Mining Company (NYSE:HL)
Hecla Mining dropped its share prices by 5.54 percent on Tuesday to close at $28.31 apiece amid concerns about a weaker production outlook for 2026, which would have benefited from a strong gold and silver market environment.
In a statement on Tuesday, Hecla Mining Company (NYSE:HL) announced projections of 15.1 million and 16.5 million ounces of consolidated silver production for 2026, or an implied decline by 3 to 11 percent from the 17.03 million ounces in 2025 amid expected lower milled grades at Greens Creek.
Gold production, on the other hand, is targeted at 134,000 to 146,000 ounces, or a decrease of 3 to 10.9 percent from the 150,509 ounces last year as it expects lower milled grades at its Casa Berardi site.
Meanwhile, Hecla Mining Company (NYSE:HL) released preliminary results of its production performance last year, with silver production up by 5 percent from 2024 and hitting the top end of its earlier guidance.
All sites hit the company’s production range outlook, with Lucky Friday producing 5.3 million ounces and exceeding the top end of its guidance range.
Meanwhile, gold production hit 150,509 ounces, exceeding its outlook by 509 ounces.
“Our 2025 results demonstrate operational excellence, with 17 million ounces of silver production and every primary silver operation meeting or exceeding guidance. We’re now accelerating investments in our future—nearly doubling our investment in exploration and pre-development to a record $55 million—while maintaining the financial discipline that positions us to generate substantial free cash flow. This is how North America’s premier silver producer creates long-term shareholder value,” said Hecla Mining Company (NYSE:HL) President and CEO Rob Krcmarov.
Hedge Fund Resource Center